The Viability of Nonprofit Models for Developing Drugs for Neglected Diseases of Poverty

The podcast critically examines the pervasive issue of market failure in the development of drugs for "diseases of poverty," also known as neglected tropical diseases. These conditions, while primarily affecting impoverished regions globally, also manifest in pockets of poverty within wealthier nations. The core argument is that these diseases do not present a lucrative investment opportunity for traditional pharmaceutical companies or early-stage investors, leading to a significant gap in research and development. A stark example provided is the 40-50 year stagnation in new drug development for tuberculosis, particularly multi-drug resistant strains, necessitating alternative approaches like those championed by the Gates Foundation and, notably, the nonprofit TB Alliance.

The discussion highlights the TB Alliance as a compelling case study of a nonprofit operating with the efficiency of a high-end biotech company, successfully developing drugs like promid entirely through government and philanthropic funding. However, a crucial distinction is drawn regarding the sustainability of this model: unlike for-profit entities, nonprofits do not generate revenue from drug sales in the affected regions (e.g., Egypt, Bangladesh, Sub-Saharan Africa) and thus lack a continuous revenue stream for future R&D. While nonprofits inherently offer cost savings by not distributing profits to shareholders, this alone is insufficient to overcome the investment challenges for diseases of poverty, necessitating a re-evaluation of incentive structures.

Practical insights include the observation that many existing government incentives, such as R&D tax credits, are designed for for-profit companies and do not effectively benefit nonprofits. The priority review voucher system is presented as a partially successful mechanism, providing a sellable asset to companies developing drugs for neglected diseases, though its market price may not fully reflect its intended value. The podcast suggests that society needs to more thoughtfully design incentive structures that specifically empower nonprofits. Furthermore, nonprofits may possess an inherent advantage in drug distribution, leveraging greater trust and established affiliations with on-the-ground public health organizations, potentially bridging the historical antipathy between private enterprise and public health.

Broader implications extend to the future landscape of drug development, particularly with the integration of Artificial Intelligence (AI). AI is viewed as a significant boon for accelerating drug discovery and enhancing efficiency, potentially mitigating the high failure rate (90%) of drug candidates in clinical trials. The episode concludes by advocating for a balanced, multi-sectoral approach that includes nonprofits, responsible for-profit companies, and carefully crafted, evidence-based government policies. This integrated strategy, coupled with technological advancements like AI, is posited as essential for overcoming persistent market failures and addressing global health inequities effectively.

"The problem here is a classic market failure if we're talking about diseases of poverty it's not not going to be a lucrative investment."

"For 4050 years there were no new drugs developed for this disease."

"One of these drugs was developed by a nonprofit it's a group called The tuberculosis Alliance the TB Alliance."

"The challenge here is it really turns economic science head a little bit and that is there there's no sustainable source of revenues."

"What differentiates a nonprofit is simply they don't distribute their revenues or their profits to shareholders."

"The TB Alliance did take advantage of an incentive called a priority review voucher and that is because diseases um of neglected tropical diseases is the language because those developing a drug for those diseases grants you a priority review voucher that you can now sell to another company."

"I don't think we as a society we fully thought out the incentive structures to enable nonprofits to to do their part as well."

"AI is going to change a lot of things here and um one of them will certainly be drug development and Drug Discovery particularly um for health we think it's only a boon."

"90% of the best ideas the scientist have still fail when they're actually put into human subjects."